End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) - Pipeline Review, H1 2016

Published: May, 2016 | Pages: 76 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) - Pipeline Review, H1 2016

Summary

Global Markets Direct's, 'End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) - Pipeline Review, H1 2016', provides an overview of the End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) pipeline landscape. 

The report provides comprehensive information on the therapeutics under development for End-Stage Kidney Disease (End-Stage Renal Disease or ESRD), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) and features dormant and discontinued projects. 

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of End-Stage Kidney Disease (End-Stage Renal Disease or ESRD)
- The report reviews pipeline therapeutics for End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) by companies and universities/research institutes based on information derived from company and industry-specific sources 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) therapeutics and enlists all their major and minor projects
- The report assesses End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type 
- The report summarizes all the dormant and discontinued pipeline projects 
- The report reviews latest news related to pipeline therapeutics for End-Stage Kidney Disease (End-Stage Renal Disease or ESRD)


Reasons To Buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Identify and understand important and diverse types of therapeutics under development for End-Stage Kidney Disease (End-Stage Renal Disease or ESRD)
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies 
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents

Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) Overview 6
Therapeutics Development 7
Pipeline Products for End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) - Overview 7
End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) - Therapeutics under Development by Companies 8
End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) - Pipeline Products Glance 9
Late Stage Products 9
Clinical Stage Products 10
Early Stage Products 11
End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) - Products under Development by Companies 12
End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) - Companies Involved in Therapeutics Development 13
Acceleron Pharma, Inc. 13
Bayer AG 14
BioAegis Therapeutics, Inc. 15
F. Hoffmann-La Roche Ltd. 16
Ionis Pharmaceuticals, Inc. 17
Prolong Pharmaceuticals, LLC 18
End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) - Therapeutics Assessment 19
Assessment by Monotherapy Products 19
Assessment by Target 20
Assessment by Mechanism of Action 22
Assessment by Route of Administration 24
Assessment by Molecule Type 26
Drug Profiles 28
calcium succinate - Drug Profile 28
Product Description 28
Mechanism of Action 28
R&D Progress 28
IONIS-FXIRx - Drug Profile 29
Product Description 29
Mechanism of Action 29
R&D Progress 29
obinutuzumab - Drug Profile 30
Product Description 30
Mechanism of Action 30
R&D Progress 30
Recombinant Plasma Gelsolin Replacement for Renal Disease - Drug Profile 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
rivaroxaban - Drug Profile 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
Sanguinate - Drug Profile 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
sotatercept - Drug Profile 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
TNT-009 - Drug Profile 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) - Recent Pipeline Updates 45
End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) - Dormant Projects 69
End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) - Discontinued Products 70
End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) - Product Development Milestones 71
Featured News & Press Releases 71
Oct 30, 2015: Isis Pharmaceuticals Initiates Phase 2 Study of ISIS-FXI Rx in Patients with End-Stage Renal Disease on Hemodialysis 71
Nov 13, 2014: Sotatercept Data from the Phase 2a Clinical Trial in Hemodialysis Patients Presented at the American Society of Nephrology Kidney Week 2014 71
Apr 23, 2014: Acceleron and Celgene Announce Interim Clinical Data for Sotatercept Demonstrating Dose Dependent Increases in Hemoglobin in Patients with End Stage Renal Disease on Hemodialysis 71
Mar 17, 2014: Acceleron and Celgene Announce Interim Clinical Data for Sotatercept in Patients with End Stage Renal Disease on Hemodialysis at the 2014 National Kidney Foundation Spring Clinical Meeting 72
Dec 18, 2013: Acceleron Earns $7 Million Milestone Payment for Celgene's Initiation of Sotatercept Phase 2 Clinical Trial in Patients with End Stage Renal Disease on Hemodialysis 73
Appendix 75
Methodology 75
Coverage 75
Secondary Research 75
Primary Research 75
Expert Panel Validation 75
Contact Us 75
Disclaimer 76

List of Tables

Number of Products under Development for End-Stage Kidney Disease (End-Stage Renal Disease or ESRD), H1 2016 7
Number of Products under Development by Companies, H1 2016 8
Comparative Analysis by Late Stage Development, H1 2016 9
Comparative Analysis by Clinical Stage Development, H1 2016 10
Comparative Analysis by Early Stage Development, H1 2016 11
Products under Development by Companies, H1 2016 12
End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) - Pipeline by Acceleron Pharma, Inc., H1 2016 13
End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) - Pipeline by Bayer AG, H1 2016 14
End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) - Pipeline by BioAegis Therapeutics, Inc., H1 2016 15
End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) - Pipeline by F. Hoffmann-La Roche Ltd., H1 2016 16
End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) - Pipeline by Ionis Pharmaceuticals, Inc., H1 2016 17
End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) - Pipeline by Prolong Pharmaceuticals, LLC, H1 2016 18
Assessment by Monotherapy Products, H1 2016 19
Number of Products by Stage and Target, H1 2016 21
Number of Products by Stage and Mechanism of Action, H1 2016 23
Number of Products by Stage and Route of Administration, H1 2016 25
Number of Products by Stage and Molecule Type, H1 2016 27
End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) Therapeutics - Recent Pipeline Updates, H1 2016 45
End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) - Dormant Projects, H1 2016 69
End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) - Discontinued Products, H1 2016 70